[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE861851T1 - Lys(B28) Insuline. Analoge des menschlichen Insulins - Google Patents

Lys(B28) Insuline. Analoge des menschlichen Insulins

Info

Publication number
DE861851T1
DE861851T1 DE0861851T DE97121214T DE861851T1 DE 861851 T1 DE861851 T1 DE 861851T1 DE 0861851 T DE0861851 T DE 0861851T DE 97121214 T DE97121214 T DE 97121214T DE 861851 T1 DE861851 T1 DE 861851T1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
cys
leu
chain
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0861851T
Other languages
English (en)
Inventor
Per 3060 Espergaerde Balschmidt
Jens Vejlgaard 2930 Klampenborg Brange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26067619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE861851(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK721588A external-priority patent/DK721588D0/da
Priority claimed from DK477789A external-priority patent/DK477789D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE861851T1 publication Critical patent/DE861851T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (9)

DE:/€ &Rgr;:&Oacgr;·'.8&Bgr;1 Bb 1 Tl EP 97 121 214.7(0 861 851) 06· November 1998 &Ngr;&ogr;&ngr;&oacgr; Nordisk A/S N28220DE DO/AD/sh Patentansprüche
1. Pharmazeutische Zusammensetzung, umfassend
(a) ein Analogon des menschlichen Insulin mit der folgenden Formel:
&Agr;-Kette S S
H-GIy-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-
12 3 4 5 6 I 8 9 10 11 12
B-Kette S
H-Phe-Val-Y2-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val 1 2 3 4 5 6 7 8 9 10 11 12
&Agr;-Kette (Fortsetzung)
13 14 15 16 17 18 19 20 21 Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Yi-OH
B-Kette (Fortsetzung)
j
Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-13 14 15 16 17 18 19 20 21 22 23 24
B-Kette (Fortsetzung)
X1-X2-X3-X4-X5-X6
25 26 27 28 29 30
wobei Xi, X2, X3, Xs, Yi und Y2 natürlich vorkommende Aminosäure-Reste sind; wobei X4 Lys oder Arg ist; und wobei Xö ein natürlich vorkommender Aminosäure-Rest, der die C-terminale Hydroxy-Gruppe trägt, oder -OH ist; oder
:··:·.:: »D.E/:€:f?::0 881 851 T1
wobei X5 und Xo gemeinsam die C-terminale Hydroxy-Guppe bilden; oder eines seiner pharmazeutisch verträglichen Salze;
(b) einen pharmazeutisch verträglichen Träger;
(c) Zink-Ionen;
(d) ein Konservierungsmittel wie m-Kresol, Methylparaben oder Phenol; und gegebenenfalls
(e) einen Puffer wie Acetat oder Citrat.
2. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei das Analogon des Insulin bei pH 7,3 eine geringe Löslichkeit aufweist.
3. Die pharmazeutische Zusammensetzung nach Anspruch 2, wobei das Analogon des Insulin im wesentlichen monomer ist.
4. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei die pharmazeutische Zusammensetzung als eine wäßrige Lösung formuliert ist.
5. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei die pharmazeutische Zusammensetzung als eine wäßrige Suspension formuliert ist.
6. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei der pharmazeutisch verträgliche Träger eine wäßrige isotonische Lösung ist.
7. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei der pharmazeutische Zusammensetzung für die mehr als ein Analogon des Insulin enthält.
8. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei die pharmazeutische Zusammensetzung für die Verabreichung über die Schleimhaut (mucosale Verabreichung) oder für die transcutane Verabreichung formuliert
9. Die pharmazeutische Zusammensetzung nach Anspruch 1, wobei die pharmazeutische Zusammensetzung für die parenterale Verabreichung formuliert ist.
DE0861851T 1988-12-23 1989-12-21 Lys(B28) Insuline. Analoge des menschlichen Insulins Pending DE861851T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK721588A DK721588D0 (da) 1988-12-23 1988-12-23 Humaninsulinanaloger
DK477789A DK477789D0 (da) 1989-09-28 1989-09-28 Nye polypeptider

Publications (1)

Publication Number Publication Date
DE861851T1 true DE861851T1 (de) 1999-04-22

Family

ID=26067619

Family Applications (4)

Application Number Title Priority Date Filing Date
DE68928917T Expired - Fee Related DE68928917T2 (de) 1988-12-23 1989-12-21 Lys(B28) Insuline. Analogen des menschlichen Insulins
DE68928810T Expired - Fee Related DE68928810T2 (de) 1988-12-23 1989-12-21 Analoge vom menschlichen Insulin
DE0861851T Pending DE861851T1 (de) 1988-12-23 1989-12-21 Lys(B28) Insuline. Analoge des menschlichen Insulins
DE68928971T Expired - Fee Related DE68928971T2 (de) 1988-12-23 1989-12-21 Lys(B28) Insuline. Analoge des menschlichen Insulins

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE68928917T Expired - Fee Related DE68928917T2 (de) 1988-12-23 1989-12-21 Lys(B28) Insuline. Analogen des menschlichen Insulins
DE68928810T Expired - Fee Related DE68928810T2 (de) 1988-12-23 1989-12-21 Analoge vom menschlichen Insulin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68928971T Expired - Fee Related DE68928971T2 (de) 1988-12-23 1989-12-21 Lys(B28) Insuline. Analoge des menschlichen Insulins

Country Status (17)

Country Link
US (1) US5164366A (de)
EP (3) EP0861851B1 (de)
JP (1) JPH04502465A (de)
KR (1) KR910700262A (de)
CN (1) CN1043719A (de)
AT (3) ATE178908T1 (de)
AU (1) AU641631B2 (de)
CA (1) CA2006578A1 (de)
DE (4) DE68928917T2 (de)
ES (1) ES2134669T3 (de)
FI (1) FI913037A0 (de)
HU (1) HUT56857A (de)
IL (1) IL92853A0 (de)
NO (1) NO301483B1 (de)
NZ (1) NZ231936A (de)
WO (1) WO1990007522A1 (de)
YU (1) YU243689A (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AU3562195A (en) * 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
CN1069649C (zh) * 1996-01-25 2001-08-15 中国科学院上海生物化学研究所 [b9谷氨酸,b10门冬氨酸]人胰岛素
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
WO1999021578A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
ES2230727T3 (es) * 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US6852694B2 (en) * 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CN1247616C (zh) * 2002-07-19 2006-03-29 上海中科生龙达生物技术（集团）有限公司 新的单体胰岛素，药物组合物及其制法
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
EP1959017A1 (de) 2003-06-17 2008-08-20 SemBioSys Genetics Inc. Verfahren zur Insulinproduktion in Pflanzen
SI2107069T1 (sl) 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
EP2264065B1 (de) 2003-08-05 2017-03-08 Novo Nordisk A/S Neue insulinderivate
ES2727854T3 (es) 2003-11-20 2019-10-21 Novo Nordisk As Formulaciones de péptidos que contienen propilenglicol que son óptimas para la producción y para su uso en dispositivos de inyección
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
CN1909930B (zh) 2004-01-21 2015-12-16 诺和诺德医疗保健公司 转谷氨酰胺酶介导的肽的接合
WO2006014673A2 (en) * 2004-07-19 2006-02-09 Nobex Corporation Insulin-oligomer conjugates, formulations and uses thereof
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2292653B1 (de) 2005-02-02 2014-05-21 Novo Nordisk A/S Neuartige Insulinderivate
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1862174A1 (de) * 2005-03-02 2007-12-05 Ajinomoto Co., Inc. Mittel zur hemmung der insulin-polymer-bildung
WO2007020256A1 (en) 2005-08-16 2007-02-22 Novo Nordisk A/S Method for making mature insulin polypeptides
ATE517919T1 (de) 2005-09-14 2011-08-15 Sanofi Aventis Deutschland Spaltung von insulinvorstufen durch eine trypsinvariante
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
EP2241327A1 (de) 2006-03-15 2010-10-20 Novo Nordisk A/S Mischung von Amylin und Insulin
ES2395738T3 (es) 2006-05-09 2013-02-14 Novo Nordisk A/S Derivado de insulina
EP2024390B1 (de) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulinderivate
EP2021368A4 (de) * 2006-06-08 2010-01-20 Diabecore Medical Inc Derivatisierte insulinoligomere
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CN101677944A (zh) 2007-06-01 2010-03-24 诺沃-诺迪斯克有限公司 稳定的非含水药物组合物
EP2514406A1 (de) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontan dispergierbare Vorkonzentrate mit einem Peptidwirkstoff in einem festen oder halbfesten Träger
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
PL2203181T3 (pl) 2007-10-16 2018-07-31 Biocon Limited Podawana doustnie stała kompozycja farmaceutyczna i jej sposób
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
ES2613152T3 (es) 2008-01-09 2017-05-22 Sanofi-Aventis Deutschland Gmbh Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
CA3016451A1 (en) * 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
WO2011003820A1 (de) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
MX2012000304A (es) 2009-07-06 2012-01-27 Sanofi Aventis Deutschland Preparaciones insulinicas que comprenden metionina.
TW201113032A (en) 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
WO2011012719A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Long acting insulin composition
WO2011012718A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs comprising an insulin linker conjugate
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
PT3572091T (pt) 2010-08-17 2024-03-01 Ambrx Inc Polipéptidos de relaxina modificados e as suas utilizações
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (de) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrug mit einem exendinbindenden Konjugat
WO2012055967A2 (en) 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HUE027989T2 (en) 2011-08-29 2016-11-28 Sanofi Aventis Deutschland A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9458219B2 (en) 2011-12-15 2016-10-04 Shanghai Hengrui Pharmaceutical Co., Ltd. Human insulin analogue and acylated derivative thereof
CA2872083A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (de) 2012-06-04 2017-02-22 Diamedica Inc. Kallikrein-1-glycosylierungsisoformen aus menschlichem gewebe
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
US9707275B2 (en) 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
RU2015130613A (ru) 2012-12-26 2017-01-31 Вокхардт Лимитед Фармацевтическая композиция
KR20140088837A (ko) 2013-01-03 2014-07-11 한미약품 주식회사 Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
AU2014326181A1 (en) 2013-09-30 2016-03-17 Wockhardt Limited Pharmaceutical composition
RU2673185C2 (ru) 2013-10-07 2018-11-22 Ново Нордиск А/С Новое производное аналога инсулина
BR112016013832A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN104017809A (zh) * 2014-06-05 2014-09-03 山东省农业科学院生物技术研究中心 改造的人Insulin蛋白表达基因及表达方法
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
HUE062573T2 (hu) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Glargin inzulin/lixiszenatid rögzített arányú készítmény
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
CN105440125B (zh) * 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
IL300839B2 (en) 2016-12-16 2024-04-01 Novo Nordisk As Pharmaceutical preparations containing insulin
JP2020510023A (ja) 2017-03-09 2020-04-02 ダイアメディカ， インコーポレイテッド 組織カリクレイン１の剤形
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
US11207384B2 (en) 2017-06-01 2021-12-28 Eli Lilly And Company Rapid-acting insulin compositions
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump for administering an insulin compound
CA3094308A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN112004521A (zh) 2018-04-04 2020-11-27 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20220119730A (ko) 2019-12-30 2022-08-30 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 인슐린 유도체
MX2022008139A (es) 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
CN114075275A (zh) * 2020-08-17 2022-02-22 成都奥达生物科技有限公司 一种长效胰岛素类似物
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
CN115493919B (zh) * 2022-11-21 2023-04-07 保定佳瑞源生物芯片有限公司 一种c肽和胰岛素检测试剂盒的校准品稀释液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426061A (en) * 1972-12-28 1976-02-25 Ici Ltd Polypeptides
JPS55138393A (en) * 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE10075034I1 (de) * 1987-02-25 2001-05-23 Novo Nordisk As Insulinderivate
DK257988D0 (da) * 1988-05-11 1988-05-11 Novo Industri As Nye peptider
IL93282A (en) * 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues

Also Published As

Publication number Publication date
EP0861851A1 (de) 1998-09-02
ATE170875T1 (de) 1998-09-15
DE68928971T2 (de) 1999-12-02
EP0837072A2 (de) 1998-04-22
JPH04502465A (ja) 1992-05-07
ATE178908T1 (de) 1999-04-15
DE68928971D1 (de) 1999-05-27
DE68928917D1 (de) 1999-03-04
CN1043719A (zh) 1990-07-11
FI913037A0 (fi) 1991-06-20
EP0837072B1 (de) 1999-01-20
AU641631B2 (en) 1993-09-30
NO912438L (no) 1991-08-21
ATE175974T1 (de) 1999-02-15
EP0861851B1 (de) 1999-04-14
US5164366A (en) 1992-11-17
NZ231936A (en) 1992-04-28
DE68928917T2 (de) 1999-08-05
CA2006578A1 (en) 1990-06-23
HUT56857A (en) 1991-10-28
EP0837072A3 (de) 1998-08-19
ES2134669T3 (es) 1999-10-01
IL92853A0 (en) 1990-09-17
DE68928810D1 (de) 1998-10-15
EP0375437A2 (de) 1990-06-27
EP0375437B1 (de) 1998-09-09
KR910700262A (ko) 1991-03-14
WO1990007522A1 (en) 1990-07-12
AU4834490A (en) 1990-08-01
YU243689A (en) 1991-10-31
NO912438D0 (no) 1991-06-21
DE68928810T2 (de) 1999-03-18
NO301483B1 (no) 1997-11-03
EP0375437A3 (de) 1991-09-11

Similar Documents

Publication Publication Date Title
DE861851T1 (de) Lys(B28) Insuline. Analoge des menschlichen Insulins
EP0132769B1 (de) Pharmazeutisches Mittel zur Behandlung des Diabetes mellitus
DE69935229T2 (de) Neue antidiabetische peptide
DE69033889T2 (de) Insulinanaloge
DE69831673T2 (de) Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
DE69722397T2 (de) Insulin-derivate und ihre verwendung
EP0885961B1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt
DE3686200T2 (de) Biologisch wirksame lysin enthaltende octapeptide.
DE69015811T2 (de) Insulinverbindungen.
DE3326472A1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
EP0821006B1 (de) Insulinderivate mit erhöhter Zinkbindung
DE3587164T2 (de) Antidiabetikaverbindungen.
US20110021423A1 (en) Rapid Acting Insulin Analogues
DD244345A5 (de) Neue peptide
NO178914B (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av Diabetes mellitus
KR930009591A (ko) 트리-아르기닌 인슐린
AT396475B (de) Säureadditionssalze aus amidiertem taurin oder glycin, deren herstellung und verwendung
EP1084248B1 (de) Neue insulinanaloga mit erhöhter zinkbindung
CH650679A5 (de) Gegen diabetes mellitus wirksames pharmazeutisches mittel.
DE69014115T2 (de) Stabilisierte, starke grf-analoga.
DE2830489A1 (de) Psychopharmakologisch wirksame peptide
EP0137361B1 (de) In Position B 30 modifizierte Insulin-Derivate, Verfahren zu deren Herstellung und deren Verwendung sowie pharmazeutische Mittel zur Behandlung des Diabetes mellitus
CA1176159A (en) Pharmaceutical formulations comprising human insulin, human c-peptide, and human proinsulin
DE3687042T2 (de) Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
DD289545A5 (de) Verfahren zur herstellung von neuen peptiden